[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526188":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EBV-HLH patients with intestinal involvement",null,"Epstein-Barr virus associated hemophagocytic lymphohistiocytosis patients with imaging confirmed intestinal involvement",[13],"Other: Segmental bowel resection combined with the DEP regimen",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Segmental bowel resection combined with the DEP regimen","Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles",[9],[20],{"name":21,"affiliation":5,"role":22},"Zhao Wang, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","63138303","wangzhao@ccmu.edu.cn",[29],{"facility":30,"status":10,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Zhao Wang","Beijing","Beijing Municipality","100050","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":22,"investigatorFullName":30,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor and Head of hematology","100526188","segmental-resection-combined-with-dep-regimen-for-ebv-hlh-patients-with-intestinal-involvement-100526188",false,"NCT06131489","Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement","Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* EBV-DNA in the peripheral blood \\> 1000 copies\u002Fml or EBV-encoded small RNA (EBER) detected in tissues;\n* Imaging revealed severe intestinal lesions and biopsy confirmed EBV-encoded small RNA (EBER) in the tissues;\n* Age \\>18 years old, gender is not limited;\n* Estimated survival time \\> 1 month;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Active infections (viral, bacterial, fungal or parasitic);\n* Diagosed with malignant tumos within 5 years；\n* Uncontrolled symptoms or other diseases including, but not limited to, unstable angina pectoris, arrhythmia, respiratory failure, severe hepatic or renal insufficiency, severe coagulation dysfunction, mental illness, or other conditions deemed by the attending physician to be contraindications to surgery;\n* Heart function above grade II (NYHA);\n* Severe myocardial injury：TNT、TNI、CK-MB \\> 3 ULN;\n* Accumulated dose of doxorubicin above 400mg\u002Fm2 、epirubicin above 750mg\u002Fm2、pirarubicin above 800mg\u002Fm2 or the patients treated with anthracycline induced cardiovascular disease;\n* Pregnancy or lactating Women;\n* Allergic to pegylated liposomal doxorubicin and etoposide;\n* HIV antibody positivity;\n* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable);\n* Participate in other clinical research at the same time;\n* The researchers considered that patients are not suitable for the study.","ALL","18 Years",{"count":56,"type":57},20,"ESTIMATED","OBSERVATIONAL","EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.",[61,62,63],"Hemophagocytic Lymphohistiocytosis","Epstein-Barr Virus","Bowel Resection","NOT_YET_RECRUITING","2023-11-09",{"date":67,"type":68},"2023-11-14","ACTUAL",{"date":70,"type":57},"2023-12-01",{"date":72,"type":57},"2027-01-01",{"name":5,"class":6},1]